Metagenomi Therapeutics, Inc. - 8-K Filing

Metagenomi Therapeutics issues November 2026 corporate presentation detailing MGX-001 clinical path and $101.7M cash position. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $MGX

Read the full article at SEC EDGAR

More Regulatory news